Match!
Paul T. Fanta
University of California, San Diego
82Publications
19H-index
1,392Citations
Publications 82
Newest
#1In Sil Choi (UCSD: University of California, San Diego)H-Index: 1
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 9 authors...
Molecular profiling of circulating tumor DNA (ctDNA) is a promising non-invasive tool. Here, next-generation sequencing (NGS) of blood-derived ctDNA was performed in patients with advanced colorectal cancer (CRC). We investigated ctDNA-derived genomic alterations, including potential actionability, concordance with tissue NGS, and serial dynamics in 78 patients with CRC using a clinical-grade NGS assay that detects single nucleotide variants (54-73 genes) and selected copy number variants, fusio...
Source
#1Emelia Stuart (UCSD: University of California, San Diego)
#2Sudeep Banerjee (UCSD: University of California, San Diego)H-Index: 2
Last.Jason K. Sicklick (UCSD: University of California, San Diego)H-Index: 25
view all 10 authors...
Source
#1Jaffer A. Ajani (University of Texas MD Anderson Cancer Center)H-Index: 89
#2Thomas A. D Amico (Duke University)H-Index: 50
Last.Lenora A. Pluchino (National Comprehensive Cancer Network)H-Index: 1
view all 38 authors...
12 CitationsSource
#1Jason K. Sicklick (UCSD: University of California, San Diego)H-Index: 25
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies1. Tumor complexity and heterogeneity suggest that the ‘precision medicine’ paradigm of cancer therapy requires treatment to be personalized to the individual patient2–6. To date, precision oncology trials have been based on molecular matching with predetermined monotherapies7–14. Several of these trials have been hindered by ve...
14 CitationsSource
#1Andrew E. HendifarH-Index: 3
#2Maria Q.B. PetzelH-Index: 1
Last.Lynn M. MatrisianH-Index: 78
view all 38 authors...
4 CitationsSource
#1Shumei KatoH-Index: 12
#2Ryosuke OkamuraH-Index: 6
Last.Razelle KurzrockH-Index: 99
view all 14 authors...
PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA) across diverse cancers and the role of anti-EGFR therapies in achieving response.MethodsWe assessed EGFR amplification status among 28,584 patients with malignancies evaluated by clinical-grade next-generation sequencing (NGS) of blood-derived cfDNA ...
2 CitationsSource
#1Shumei KatoH-Index: 12
#2Maria SchwaederleH-Index: 18
Last.Razelle KurzrockH-Index: 99
view all 10 authors...
PurposeGenomic alterations in blood-derived circulating tumor DNA (ctDNA) from patients with colorectal cancers were correlated with clinical outcomes.Patients and MethodsNext-generation sequencing of ctDNA (54- to 73-gene panel) was performed in 94 patients with colorectal cancer.ResultsMost patients (96%) had metastatic or recurrent disease at the time of blood draw. The median number of nonsynonymous alterations per patient was three (range, zero to 30). The most frequently aberrant genes wer...
3 CitationsSource
#1Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
#2Ryosuke Okamura (UCSD: University of California, San Diego)H-Index: 6
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
Purpose: Esophageal, gastroesophageal junction, and gastric adenocarcinoma (herein gastroesophageal adenocarcinomas) are associated with poor prognosis and limited systemic treatment options. To further understand the genomic landscape of gastroesophageal cancers and its clinical correlations, circulating tumor DNA (ctDNA) from patients’ plasma was evaluated using next-generation sequencing (NGS). Experimental Design: We analyzed genomic alterations of 55 patients (mostly advanced disease; 9, su...
9 CitationsSource
#1Celina S.-P. AngH-Index: 1
#2John Paul ShenH-Index: 11
Last.Olivier HarismendyH-Index: 24
view all 16 authors...
PurposeAppendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers and novel therapeutic targets.MethodsTumor specimens were submitted to a Clinical Laboratory Improvement Amendments–certified laboratory (Foundation Medicine, Cambridge,...
3 CitationsSource
#1Manisha H. Shah (OSU: Ohio State University)H-Index: 33
#2Whitney S GoldnerH-Index: 16
Last.Griselda Zuccarino-Catania (National Comprehensive Cancer Network)H-Index: 4
view all 36 authors...
25 CitationsSource
123456789